United States Pharmaceuticals

Gritstone Oncology Inc (GRTS)

Track

Track

Ticker: GRTS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Gritstone Oncology Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.7
Economides Vassiliki EVP, CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
448.66
Quantity 52,200 +48.7%
Value US$1,409,930
1.7
Economides Vassiliki Officer Officer
Transaction date
Proposed sale
Price
117.43
Quantity 13,013
Value US$4,012,910
2.5
Allen Andrew R PRESIDENT AND CEO Executive Director
Transaction date
Sale
Price
220.53
Quantity 53,940 +15.3%
Value US$3,634,579
1.7
Economides Vassiliki EVP, CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
0.75
Quantity 13,749 -5.0%
Value US$10,288
2.5
Hawryluk Matthew EVP, CHIEF BUSINESS OFFICER Officer
Transaction date
Sale
Price
0.75
Quantity 9,259 -2.9%
Value US$6,929
2.1
Jooss Karin SEE REMARKS Officer
Transaction date
Sale
Price
0.75
Quantity 13,749 -2.0%
Value US$10,288
3.2
Jones Erin EVP, CHIEF OPERATING OFFICER Officer
Transaction date
Sale
Price
0.75
Quantity 13,749 -3.7%
Value US$10,288
1.7
Economides Vassiliki See Remarks Officer
Transaction date
Purchase
Price
1.90
Quantity 12,000 +5.9%
Value US$22,829
3.2
Jones Erin Chief Operating Officer Officer
Transaction date
Planned sale
Price
13.01
Quantity 1,000 -2.1%
Value US$13,010
3.2
Jones Erin See Remarks Officer
Transaction date
Planned sale
Price
11.14
Quantity 1,000 -4.8%
Value US$11,140
3.2
Jones Erin See Remarks Officer
Transaction date
Planned sale
Price
10.71
Quantity 1,000 -4.8%
Value US$10,710
3.2
Jones Erin See Remarks Officer
Transaction date
Planned sale
Price
10.68
Quantity 1,000 -4.8%
Value US$10,680
0.8
Rousseau Raphael See Remarks Officer
Transaction date
Sale
Price
9.00
Quantity 2,900 -100.0%
Value US$26,112
0.8
Rousseau Raphael See Remarks Officer
Transaction date
Planned sale
Price
25.07
Quantity 10,000 -100.0%
Value US$250,705
0.8
Rousseau Raphael See Remarks Officer
Transaction date
Planned sale
Price
17.53
Quantity 20,000 -100.0%
Value US$350,564
3.3
Yelensky Roman See Remarks Officer
Transaction date
Sale
Price
22.10
Quantity 10,000 -7.0%
Value US$221,029
3.8
Woiwode Thomas Non-Executive Director
Transaction date
Purchase
Price
3.71
Quantity 1,347,709 +inf%
Value US$5,000,000
3.2
Rousseau Raphael See Remarks Officer
Transaction date
Sale
Price
10.76
Quantity 10,000 -100.0%
Value US$107,631
2.3
Simon Nicholas Non-Executive Director Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 333,333 +inf%
Value US$4,999,995
Clarus Lifesciences III, L.P. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 333,333 +inf%
Value US$4,999,995
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-12-20 2024-12-18 S Sale
1.7
Economides Vassiliki

EVP, CHIEF FINANCIAL OFFICER

Officer
52,200 +48.7%
448.66
US$1,409,930 		52,200 +48.7% 448.66 US$1,409,930
2024-12-18 2024-12-18 PrS Proposed sale
1.7
Economides Vassiliki

Officer

Officer
13,013
117.43
US$4,012,910 		13,013 117.43 US$4,012,910
2024-05-17 2024-05-16 S Sale
2.5
Allen Andrew R

PRESIDENT AND CEO

Executive Director
53,940 +15.3%
220.53
US$3,634,579 		53,940 +15.3% 220.53 US$3,634,579
2024-05-17 2024-05-16 S Sale
1.7
Economides Vassiliki

EVP, CHIEF FINANCIAL OFFICER

Officer
13,749 -5.0%
0.75
US$10,288 		13,749 -5.0% 0.75 US$10,288
2024-05-17 2024-05-16 S Sale
2.5
Hawryluk Matthew

EVP, CHIEF BUSINESS OFFICER

Officer
9,259 -2.9%
0.75
US$6,929 		9,259 -2.9% 0.75 US$6,929
2024-05-17 2024-05-16 S Sale
2.1
Jooss Karin

SEE REMARKS

Officer
13,749 -2.0%
0.75
US$10,288 		13,749 -2.0% 0.75 US$10,288
2024-05-17 2024-05-16 S Sale
3.2
Jones Erin

EVP, CHIEF OPERATING OFFICER

Officer
13,749 -3.7%
0.75
US$10,288 		13,749 -3.7% 0.75 US$10,288
2023-05-24 2023-05-23 B Purchase
1.7
Economides Vassiliki

See Remarks

Officer
12,000 +5.9%
1.90
US$22,829 		12,000 +5.9% 1.90 US$22,829
2021-12-03 2021-12-01 PlS Planned sale
3.2
Jones Erin

Chief Operating Officer

Officer
1,000 -2.1%
13.01
US$13,010 		1,000 -2.1% 13.01 US$13,010
2021-11-03 2021-11-01 PlS Planned sale
3.2
Jones Erin

See Remarks

Officer
1,000 -4.8%
11.14
US$11,140 		1,000 -4.8% 11.14 US$11,140
2021-10-05 2021-10-04 PlS Planned sale
3.2
Jones Erin

See Remarks

Officer
1,000 -4.8%
10.71
US$10,710 		1,000 -4.8% 10.71 US$10,710
2021-10-05 2021-10-01 PlS Planned sale
3.2
Jones Erin

See Remarks

Officer
1,000 -4.8%
10.68
US$10,680 		1,000 -4.8% 10.68 US$10,680
2021-06-03 2021-05-27 S Sale
0.8
Rousseau Raphael

See Remarks

Officer
2,900 -100.0%
9.00
US$26,112 		2,900 -100.0% 9.00 US$26,112
2021-01-21 2021-01-20 PlS Planned sale
0.8
Rousseau Raphael

See Remarks

Officer
10,000 -100.0%
25.07
US$250,705 		10,000 -100.0% 25.07 US$250,705
2021-01-21 2021-01-19 PlS Planned sale
0.8
Rousseau Raphael

See Remarks

Officer
20,000 -100.0%
17.53
US$350,564 		20,000 -100.0% 17.53 US$350,564
2021-01-21 2021-01-19 S Sale
3.3
Yelensky Roman

See Remarks

Officer
10,000 -7.0%
22.10
US$221,029 		10,000 -7.0% 22.10 US$221,029
2021-01-04 2020-12-30 B Purchase
3.8
Woiwode Thomas
Non-Executive Director
1,347,709 +inf%
3.71
US$5,000,000 		1,347,709 +inf% 3.71 US$5,000,000
2019-08-23 2019-08-21 S Sale
3.2
Rousseau Raphael

See Remarks

Officer
10,000 -100.0%
10.76
US$107,631 		10,000 -100.0% 10.76 US$107,631
2018-10-02 2018-09-28 B Purchase
2.3
Simon Nicholas
Non-Executive Director Large shareholder
333,333 +inf%
15.00
US$4,999,995 		333,333 +inf% 15.00 US$4,999,995
2018-10-02 2018-09-28 B Purchase Clarus Lifesciences III, L.P. Large shareholder
333,333 +inf%
15.00
US$4,999,995 		333,333 +inf% 15.00 US$4,999,995
Explore more

More insider trading research around Gritstone Oncology Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America